Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Portfolio Pulse from
Intellia Therapeutics (NTLA) is being sued for securities law violations related to alleged misleading statements about its NTLA-3001 research program. The lawsuit claims the company failed to disclose declining demand for viral-based editing and subsequently halted the program, leading to a 15% stock price drop in January 2025.
April 11, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Class action lawsuit alleges securities fraud related to NTLA-3001 research program, potentially impacting investor confidence and stock performance.
The lawsuit directly targets Intellia Therapeutics, alleging securities fraud by not disclosing critical information about its research program. The stock price already dropped 15% following the announcement, and ongoing legal proceedings could further impact investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100